To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catete... more To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catetenin, adenomatous polyposis coli, GSK3β, axin and ubiquitin in colorectal carcinoma and colonic adenoma. Tissue samples from 64 patients with colorectal carcinoma and 53 patients with colonic adenoma were analyzed. Tissue microarray blocks and slides were prepared and subjected to immunohistochemistry with polyclonal antibodies in carcinoma, adjacent non-neoplastic mucosa, and adenoma tissues. The immunoreactivity was evaluated by the percentage of positive stained cells and by the intensity assessed through of the stained grade of proteins in the cytoplasm and nucleus of cells. In the statistical analysis, the Spearman correlation coefficient, Student's t, χ2, Mann-Whitney, and McNemar tests, and univariate logistic regression analysis were used. In colorectal carcinoma, the expressions of beta-catenin and adenomatous polyposis coli proteins were significantly higher than in colonic ...
Objective: To perform an analysis of the costs of treatment of varicose ulcers by radical surgery... more Objective: To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices and the use of Unna boot. Methods: Fifteen outpatients were selected to receive treatment of varicose ulcers with radical surgery and Unna boot. The total cost of treatment was calculated (hospitalization, surgery, dressings, and outpatient's follow-up visits) and compared to the cost of clinical follow-up with daily simple dressing changes. Results: The proposed treatment was on average 55.71% more economical than the management with daily dressings (approximately US$452.32 versus US$1,021.39). Conclusion: Radical varicose vein surgery associated with the use of the Unna boot proved meaningly less expensive for the public health system than clinical follow-up with daily dressings.
BACKGROUND Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump i... more BACKGROUND Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. OBJECTIVES To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. PATIENTS/METHODS A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a dail...
To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catete... more To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catetenin, adenomatous polyposis coli, GSK3β, axin and ubiquitin in colorectal carcinoma and colonic adenoma. Tissue samples from 64 patients with colorectal carcinoma and 53 patients with colonic adenoma were analyzed. Tissue microarray blocks and slides were prepared and subjected to immunohistochemistry with polyclonal antibodies in carcinoma, adjacent non-neoplastic mucosa, and adenoma tissues. The immunoreactivity was evaluated by the percentage of positive stained cells and by the intensity assessed through of the stained grade of proteins in the cytoplasm and nucleus of cells. In the statistical analysis, the Spearman correlation coefficient, Student's t, χ2, Mann-Whitney, and McNemar tests, and univariate logistic regression analysis were used. In colorectal carcinoma, the expressions of beta-catenin and adenomatous polyposis coli proteins were significantly higher than in colonic ...
Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors t... more Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a daily basis. One hundred and sixty two patients completed the study in accordance with the protocol. Reflux esophagitis was diagnosed in 78 (48.1%) patients, duodenal ulcer in 39 (24.1%) and gastric ulcer in 24 (14.8%). Eleven (6.8%) patients presented reflux esophagitis associated with duodenal ulcer and 7 (4.3%) associated with gastric ulcer. Finally, 3 (1.9%) presented both gastric and duodenal ulcer. Fifty-three percentage of patients were free of symptoms on the first day of treatment and 89.5% after a week. The healing rate was 84.4% for patients with reflux esophagitis, 90.6% for duodenal ulcer and 90.9% for gastric ulcer. The adverse effects were minimal and transitory. Rabeprazole is highly effective and well tolerated in acute healing of reflux esophagitis and peptic ulcers. In addition, it provides fast symptoms relief.
To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices... more To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices and the use of Unna boot. Fifteen outpatients were selected to receive treatment of varicose ulcers with radical surgery and Unna boot. The total cost of treatment was calculated (hospitalization, surgery, dressings, and outpatient's follow-up visits) and compared to the cost of clinical follow-up with daily simple dressing changes. The proposed treatment was on average 55.71% more economical than the management with daily dressings (approximately US$452.32 versus US$1,021.39). Radical varicose vein surgery associated with the use of the Unna boot proved meaningly less expensive for the public health system than clinical follow-up with daily dressings.
To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices... more To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices and the use of Unna boot. Fifteen outpatients were selected to receive treatment of varicose ulcers with radical surgery and Unna boot. The total cost of treatment was calculated (hospitalization, surgery, dressings, and outpatient's follow-up visits) and compared to the cost of clinical follow-up with daily simple dressing changes. The proposed treatment was on average 55.71% more economical than the management with daily dressings (approximately US$452.32 versus US$1,021.39). Radical varicose vein surgery associated with the use of the Unna boot proved meaningly less expensive for the public health system than clinical follow-up with daily dressings.
Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors t... more Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a daily basis. One hundred and sixty two patients completed the study in accordance with the protocol. Reflux esophagitis was diagnosed in 78 (48.1%) patients, duodenal ulcer in 39 (24.1%) and gastric ulcer in 24 (14.8%). Eleven (6.8%) patients presented reflux esophagitis associated with duodenal ulcer and 7 (4.3%) associated with gastric ulcer. Finally, 3 (1.9%) presented both gastric and duodenal ulcer. Fifty-three percentage of patients were free of symptoms on the first day of treatment and 89.5% after a week. The healing rate was 84.4% for patients with reflux esophagitis, 90.6% for duodenal ulcer and 90.9% for gastric ulcer. The adverse effects were minimal and transitory. Rabeprazole is highly effective and well tolerated in acute healing of reflux esophagitis and peptic ulcers. In addition, it provides fast symptoms relief.
Infrapopliteal mycotic aneurysm resulting from endocarditis is rare, with only a few reported cas... more Infrapopliteal mycotic aneurysm resulting from endocarditis is rare, with only a few reported cases. We describe the case of a 28-year-old male patient who was suffering with pain and edema in the right leg. The ultrasound revealed an aneurysm of the right tibioperoneal trunk and a deep vein thrombosis (DVT). The patient was admitted and developed acute congestive heart failure, being diagnosed with possible endocarditis. A pseudo-aneurysm was revealed by arteriography. Aggressive antibiotic treatment was initiated, and open surgery confirmed a mycotic pseudo-aneurysm of the tibioperoneal trunk. To our knowledge, this is the 8 th case reported of an infected aneurysm in this particular location.
-Rabeprazol sódico é um derivado benzimidazólico com potente ação inibidora da bomba de prótons. ... more -Rabeprazol sódico é um derivado benzimidazólico com potente ação inibidora da bomba de prótons. Aprovado na maioria dos países do mundo, inclusive no Brasil, a substância tem se mostrado muito eficaz para o tratamento das doenças ácido-pépticas, especialmente a doença por refluxo gastroesofágico. Objetivos -Avaliar a eficácia e tolerabilidade de rabeprazol em pacientes com esofagite por refluxo e/ou úlcera péptica gástrica e/ou duodenal na prática clínica, bem como avaliar o tempo necessário para a obtenção de alívio dos sintomas. Pacientes/Métodos -Foram avaliados 171 pacientes que procuraram consulta com gastroenterologista e que tiveram como diagnóstico a doença por refluxo ou úlcera péptica. Todos os pacientes eram ambulatoriais, de ambos os sexos, com idade superior a 18 anos. O diagnóstico, assim como o controle póstratamento foi obtido através do exame endoscópico. Todos os pacientes receberam 20 mg de rabeprazol ao dia por 4 a 8 semanas, dependendo do diagnóstico e a critério do médico. Os pacientes receberam um diário para registro do início do alívio dos sintomas. Os dados obtidos no inicio e ao final do tratamento foram analisados através do teste não-paramétrico de Wilcoxon para amostras pareadas. Resultados -Dos 171 pacientes iniciais 162 completaram o estudo. Destes, 78 (48,1%) tiveram como diagnóstico a doença por refluxo. Onze (6,8%) apresentaram associação desta com úlcera duodenal e 7 (4,3%) associado à úlcera gástrica. Em 39 (24,1%) o diagnóstico foi de úlcera duodenal. A úlcera gástrica isoladamente estava presente em 24 (14,8%) e associada à úlcera duodenal em 3 (1,9%) casos. O tratamento foi de 4 semanas em 94,2% dos pacientes. Apenas 7 necessitaram 6 semanas e 3 foram tratados por 8 semanas. Mais da metade dos pacientes obtiveram alívio dos sintomas após o 1 dia de tratamento e após 7 dias, 89,5% estavam totalmente assintomáticos. O índice de cicatrização das lesões foi de 88,3% dos casos. Vinte e sete pacientes (15,2%) relataram eventos adversos leves que não necessariamente estavam relacionados à medicação, sendo os mais freqüentes: diarréia, cefaléia e tonturas. Conclusões -O rabeprazol mostrouse altamente eficaz para o alívio dos sintomas de pacientes com doenças ácido-pépticas. Da mesma forma, a droga proporcionou altos índices de cicatrização das lesões. O medicamento mostrou ser seguro, com efeitos colaterais transitórios e sem maiores conseqüências para os pacientes.
To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catete... more To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catetenin, adenomatous polyposis coli, GSK3β, axin and ubiquitin in colorectal carcinoma and colonic adenoma. Tissue samples from 64 patients with colorectal carcinoma and 53 patients with colonic adenoma were analyzed. Tissue microarray blocks and slides were prepared and subjected to immunohistochemistry with polyclonal antibodies in carcinoma, adjacent non-neoplastic mucosa, and adenoma tissues. The immunoreactivity was evaluated by the percentage of positive stained cells and by the intensity assessed through of the stained grade of proteins in the cytoplasm and nucleus of cells. In the statistical analysis, the Spearman correlation coefficient, Student's t, χ2, Mann-Whitney, and McNemar tests, and univariate logistic regression analysis were used. In colorectal carcinoma, the expressions of beta-catenin and adenomatous polyposis coli proteins were significantly higher than in colonic ...
Objective: To perform an analysis of the costs of treatment of varicose ulcers by radical surgery... more Objective: To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices and the use of Unna boot. Methods: Fifteen outpatients were selected to receive treatment of varicose ulcers with radical surgery and Unna boot. The total cost of treatment was calculated (hospitalization, surgery, dressings, and outpatient's follow-up visits) and compared to the cost of clinical follow-up with daily simple dressing changes. Results: The proposed treatment was on average 55.71% more economical than the management with daily dressings (approximately US$452.32 versus US$1,021.39). Conclusion: Radical varicose vein surgery associated with the use of the Unna boot proved meaningly less expensive for the public health system than clinical follow-up with daily dressings.
BACKGROUND Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump i... more BACKGROUND Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. OBJECTIVES To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. PATIENTS/METHODS A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a dail...
To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catete... more To evaluate the destruction complex of beta-catenin by the expression of the proteins beta-catetenin, adenomatous polyposis coli, GSK3β, axin and ubiquitin in colorectal carcinoma and colonic adenoma. Tissue samples from 64 patients with colorectal carcinoma and 53 patients with colonic adenoma were analyzed. Tissue microarray blocks and slides were prepared and subjected to immunohistochemistry with polyclonal antibodies in carcinoma, adjacent non-neoplastic mucosa, and adenoma tissues. The immunoreactivity was evaluated by the percentage of positive stained cells and by the intensity assessed through of the stained grade of proteins in the cytoplasm and nucleus of cells. In the statistical analysis, the Spearman correlation coefficient, Student's t, χ2, Mann-Whitney, and McNemar tests, and univariate logistic regression analysis were used. In colorectal carcinoma, the expressions of beta-catenin and adenomatous polyposis coli proteins were significantly higher than in colonic ...
Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors t... more Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a daily basis. One hundred and sixty two patients completed the study in accordance with the protocol. Reflux esophagitis was diagnosed in 78 (48.1%) patients, duodenal ulcer in 39 (24.1%) and gastric ulcer in 24 (14.8%). Eleven (6.8%) patients presented reflux esophagitis associated with duodenal ulcer and 7 (4.3%) associated with gastric ulcer. Finally, 3 (1.9%) presented both gastric and duodenal ulcer. Fifty-three percentage of patients were free of symptoms on the first day of treatment and 89.5% after a week. The healing rate was 84.4% for patients with reflux esophagitis, 90.6% for duodenal ulcer and 90.9% for gastric ulcer. The adverse effects were minimal and transitory. Rabeprazole is highly effective and well tolerated in acute healing of reflux esophagitis and peptic ulcers. In addition, it provides fast symptoms relief.
To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices... more To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices and the use of Unna boot. Fifteen outpatients were selected to receive treatment of varicose ulcers with radical surgery and Unna boot. The total cost of treatment was calculated (hospitalization, surgery, dressings, and outpatient's follow-up visits) and compared to the cost of clinical follow-up with daily simple dressing changes. The proposed treatment was on average 55.71% more economical than the management with daily dressings (approximately US$452.32 versus US$1,021.39). Radical varicose vein surgery associated with the use of the Unna boot proved meaningly less expensive for the public health system than clinical follow-up with daily dressings.
To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices... more To perform an analysis of the costs of treatment of varicose ulcers by radical surgery of varices and the use of Unna boot. Fifteen outpatients were selected to receive treatment of varicose ulcers with radical surgery and Unna boot. The total cost of treatment was calculated (hospitalization, surgery, dressings, and outpatient's follow-up visits) and compared to the cost of clinical follow-up with daily simple dressing changes. The proposed treatment was on average 55.71% more economical than the management with daily dressings (approximately US$452.32 versus US$1,021.39). Radical varicose vein surgery associated with the use of the Unna boot proved meaningly less expensive for the public health system than clinical follow-up with daily dressings.
Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors t... more Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a daily basis. One hundred and sixty two patients completed the study in accordance with the protocol. Reflux esophagitis was diagnosed in 78 (48.1%) patients, duodenal ulcer in 39 (24.1%) and gastric ulcer in 24 (14.8%). Eleven (6.8%) patients presented reflux esophagitis associated with duodenal ulcer and 7 (4.3%) associated with gastric ulcer. Finally, 3 (1.9%) presented both gastric and duodenal ulcer. Fifty-three percentage of patients were free of symptoms on the first day of treatment and 89.5% after a week. The healing rate was 84.4% for patients with reflux esophagitis, 90.6% for duodenal ulcer and 90.9% for gastric ulcer. The adverse effects were minimal and transitory. Rabeprazole is highly effective and well tolerated in acute healing of reflux esophagitis and peptic ulcers. In addition, it provides fast symptoms relief.
Infrapopliteal mycotic aneurysm resulting from endocarditis is rare, with only a few reported cas... more Infrapopliteal mycotic aneurysm resulting from endocarditis is rare, with only a few reported cases. We describe the case of a 28-year-old male patient who was suffering with pain and edema in the right leg. The ultrasound revealed an aneurysm of the right tibioperoneal trunk and a deep vein thrombosis (DVT). The patient was admitted and developed acute congestive heart failure, being diagnosed with possible endocarditis. A pseudo-aneurysm was revealed by arteriography. Aggressive antibiotic treatment was initiated, and open surgery confirmed a mycotic pseudo-aneurysm of the tibioperoneal trunk. To our knowledge, this is the 8 th case reported of an infected aneurysm in this particular location.
-Rabeprazol sódico é um derivado benzimidazólico com potente ação inibidora da bomba de prótons. ... more -Rabeprazol sódico é um derivado benzimidazólico com potente ação inibidora da bomba de prótons. Aprovado na maioria dos países do mundo, inclusive no Brasil, a substância tem se mostrado muito eficaz para o tratamento das doenças ácido-pépticas, especialmente a doença por refluxo gastroesofágico. Objetivos -Avaliar a eficácia e tolerabilidade de rabeprazol em pacientes com esofagite por refluxo e/ou úlcera péptica gástrica e/ou duodenal na prática clínica, bem como avaliar o tempo necessário para a obtenção de alívio dos sintomas. Pacientes/Métodos -Foram avaliados 171 pacientes que procuraram consulta com gastroenterologista e que tiveram como diagnóstico a doença por refluxo ou úlcera péptica. Todos os pacientes eram ambulatoriais, de ambos os sexos, com idade superior a 18 anos. O diagnóstico, assim como o controle póstratamento foi obtido através do exame endoscópico. Todos os pacientes receberam 20 mg de rabeprazol ao dia por 4 a 8 semanas, dependendo do diagnóstico e a critério do médico. Os pacientes receberam um diário para registro do início do alívio dos sintomas. Os dados obtidos no inicio e ao final do tratamento foram analisados através do teste não-paramétrico de Wilcoxon para amostras pareadas. Resultados -Dos 171 pacientes iniciais 162 completaram o estudo. Destes, 78 (48,1%) tiveram como diagnóstico a doença por refluxo. Onze (6,8%) apresentaram associação desta com úlcera duodenal e 7 (4,3%) associado à úlcera gástrica. Em 39 (24,1%) o diagnóstico foi de úlcera duodenal. A úlcera gástrica isoladamente estava presente em 24 (14,8%) e associada à úlcera duodenal em 3 (1,9%) casos. O tratamento foi de 4 semanas em 94,2% dos pacientes. Apenas 7 necessitaram 6 semanas e 3 foram tratados por 8 semanas. Mais da metade dos pacientes obtiveram alívio dos sintomas após o 1 dia de tratamento e após 7 dias, 89,5% estavam totalmente assintomáticos. O índice de cicatrização das lesões foi de 88,3% dos casos. Vinte e sete pacientes (15,2%) relataram eventos adversos leves que não necessariamente estavam relacionados à medicação, sendo os mais freqüentes: diarréia, cefaléia e tonturas. Conclusões -O rabeprazol mostrouse altamente eficaz para o alívio dos sintomas de pacientes com doenças ácido-pépticas. Da mesma forma, a droga proporcionou altos índices de cicatrização das lesões. O medicamento mostrou ser seguro, com efeitos colaterais transitórios e sem maiores conseqüências para os pacientes.
Uploads
Papers by Hélio Fragoso